Market Cap 50.72M
Revenue (ttm) 0.00
Net Income (ttm) -12.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 217,400
Avg Vol 52,430
Day's Range N/A - N/A
Shares Out 4.98M
Stochastic %K 94%
Beta 0.47
Analysts Strong Sell
Price Target $39.00

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 994 8250
Address:
149 Fifth Avenue, Suite 500, New York, United States
iso
iso May. 28 at 6:36 PM
$INKT 10× might be Sooner.. especially after big news, stock adviser on it on YouTube
0 · Reply
iso
iso May. 28 at 5:33 PM
$INKT great,i lovevit
0 · Reply
Turnthemachinesbackon
Turnthemachinesbackon May. 28 at 5:22 PM
$INKT https://x.com/alc2022/status/2059946096915276145?s=20
0 · Reply
Quantcompass
Quantcompass May. 28 at 5:09 PM
$INKT With 3.5 quarters of cash runway the dilution here is real. Its as binary as bets can get.
0 · Reply
Quantcompass
Quantcompass May. 28 at 5:06 PM
$INKT Theres a second wave of shorts that follow antonios shills beware
0 · Reply
ultramit
ultramit May. 28 at 4:55 PM
$INKT well.. Antonio shilling this and peoples are buying. Lol
0 · Reply
enkemm
enkemm May. 28 at 2:39 PM
$INKT Very nice start for Phase 2 study treating ARDS in Ukraine. With no approved treatment, and a 40% to 50% death rate, if INKT can cut that in half.....holy mackerel. ARDS effects over 3 million people a year worldwide, 10% of all ICU admissions and roughly 23% of mechanically ventilated patients globally. IF Agent 797 did nothing other than cut mortality in half for ARDS, stockholders are golden.
0 · Reply
Spartrap
Spartrap May. 28 at 2:09 PM
$INKT this can very realistically 10x in the next six months on the back of good ARDS data. Amazing value
0 · Reply
Spartrap
Spartrap May. 28 at 1:50 PM
$INKT great execution
0 · Reply
focafoca99
focafoca99 May. 28 at 1:28 PM
$INKT starts its Phase 2 trial of agenT-797 with the first patient dosed in Ukraine.
0 · Reply
Latest News on INKT
MiNK Therapeutics doses first patient in agenT-797 trial

2026-05-28T14:12:03.000Z - 1 day ago

MiNK Therapeutics doses first patient in agenT-797 trial


MiNK Therapeutics reports new data on agenT-797 at ATS 2026

2026-05-20T15:15:48.000Z - 9 days ago

MiNK Therapeutics reports new data on agenT-797 at ATS 2026


MiNK Therapeutics Q1 Earnings Call Highlights

May 15, 2026, 10:12 AM EDT - 14 days ago

MiNK Therapeutics Q1 Earnings Call Highlights


MiNK Therapeutics Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 14 days ago

MiNK Therapeutics Earnings Call Transcript: Q1 2026


MiNK Therapeutics Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 14 days ago

MiNK Therapeutics Earnings release: Q1 2026


MiNK Therapeutics Quarterly report: Q1 2026

May 15, 2026, 8:30 AM EDT - 14 days ago

MiNK Therapeutics Quarterly report: Q1 2026


MiNK Therapeutics initiates agenT-797 clinical trial

2026-05-14T17:31:11.000Z - 14 days ago

MiNK Therapeutics initiates agenT-797 clinical trial


MiNK Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 weeks ago

MiNK Therapeutics Proxy statement: Proxy filing


MiNK Therapeutics management to meet virtually with B. Riley

2026-04-20T17:05:20.000Z - 5 weeks ago

MiNK Therapeutics management to meet virtually with B. Riley


MiNK Therapeutics Earnings Call Transcript: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Earnings Call Transcript: Q4 2025


MiNK Therapeutics Annual report: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Annual report: Q4 2025


MiNK Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Earnings release: Q4 2025


3 Penny Stocks to Watch Now, 3/11/26

2026-03-11T14:11:00.000Z - 2 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC LGVN


Why Is MiNK Therapeutics Stock (INKT) Up Today?

2026-03-10T12:33:59.000Z - 2 months ago

Why Is MiNK Therapeutics Stock (INKT) Up Today?


MiNK Therapeutics Registration statement: Registration Filing

Dec 10, 2025, 7:00 AM EST - 6 months ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Therapeutics Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:30 AM EST - 7 months ago

MiNK Therapeutics Earnings Call Transcript: Q3 2025


MiNK Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 7 months ago

MiNK Therapeutics Quarterly report: Q3 2025


MiNK Therapeutics Earnings release: Q3 2025

Nov 14, 2025, 8:30 AM EST - 7 months ago

MiNK Therapeutics Earnings release: Q3 2025


MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year

2025-11-14T12:35:56.000Z - 7 months ago

MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year


MiNK Therapeutics files $150M mixed securities shelf

2025-11-07T22:00:18.000Z - 7 months ago

MiNK Therapeutics files $150M mixed securities shelf


MiNK Therapeutics reports updated clinical results on agenT-797

2025-11-07T14:05:54.000Z - 7 months ago

MiNK Therapeutics reports updated clinical results on agenT-797


MiNK Therapeutics Registration statement: Registration Filing

Nov 7, 2025, 7:00 AM EST - 7 months ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Therapeutics appoints John Holcomb to board of directors

2025-09-29T11:45:50.000Z - 8 months ago

MiNK Therapeutics appoints John Holcomb to board of directors


MiNK Therapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 10 months ago

MiNK Therapeutics Earnings Call Transcript: Q2 2025


MiNK Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 10 months ago

MiNK Therapeutics Quarterly report: Q2 2025


MiNK Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 10 months ago

MiNK Therapeutics Earnings release: Q2 2025


MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year

2025-08-14T11:40:29.000Z - 10 months ago

MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year


H.C. Wainwright downgrades MiNK Therapeutics after 400% rally

2025-07-15T14:30:12.000Z - 11 months ago

H.C. Wainwright downgrades MiNK Therapeutics after 400% rally


MiNK Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q1 2025


MiNK Therapeutics Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q1 2025


MiNK Therapeutics Earnings release: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q1 2025


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q4 2024


MiNK Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Annual report: Q4 2024


MiNK Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q4 2024


MiNK Therapeutics Proxy statement: Proxy Filing

Dec 20, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Proxy statement: Proxy Filing

Dec 6, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q3 2024


MiNK Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Quarterly report: Q3 2024


MiNK Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings release: Q3 2024


MiNK Therapeutics Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q2 2024


MiNK Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q2 2024


MiNK Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q2 2024


MiNK Therapeutics Registration statement: Registration Filing

Aug 13, 2024, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Reports Second Quarter 2024 Results and Business Update

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update


MiNK Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q1 2024


MiNK Therapeutics Quarterly report: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q1 2024


MiNK Therapeutics Earnings release: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q1 2024


MiNK Reports First Quarter 2024 Results

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q4 2023


MiNK Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Annual report: Q4 2023


MiNK Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q4 2023


MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results


iso
iso May. 28 at 6:36 PM
$INKT 10× might be Sooner.. especially after big news, stock adviser on it on YouTube
0 · Reply
iso
iso May. 28 at 5:33 PM
$INKT great,i lovevit
0 · Reply
Turnthemachinesbackon
Turnthemachinesbackon May. 28 at 5:22 PM
$INKT https://x.com/alc2022/status/2059946096915276145?s=20
0 · Reply
Quantcompass
Quantcompass May. 28 at 5:09 PM
$INKT With 3.5 quarters of cash runway the dilution here is real. Its as binary as bets can get.
0 · Reply
Quantcompass
Quantcompass May. 28 at 5:06 PM
$INKT Theres a second wave of shorts that follow antonios shills beware
0 · Reply
ultramit
ultramit May. 28 at 4:55 PM
$INKT well.. Antonio shilling this and peoples are buying. Lol
0 · Reply
enkemm
enkemm May. 28 at 2:39 PM
$INKT Very nice start for Phase 2 study treating ARDS in Ukraine. With no approved treatment, and a 40% to 50% death rate, if INKT can cut that in half.....holy mackerel. ARDS effects over 3 million people a year worldwide, 10% of all ICU admissions and roughly 23% of mechanically ventilated patients globally. IF Agent 797 did nothing other than cut mortality in half for ARDS, stockholders are golden.
0 · Reply
Spartrap
Spartrap May. 28 at 2:09 PM
$INKT this can very realistically 10x in the next six months on the back of good ARDS data. Amazing value
0 · Reply
Spartrap
Spartrap May. 28 at 1:50 PM
$INKT great execution
0 · Reply
focafoca99
focafoca99 May. 28 at 1:28 PM
$INKT starts its Phase 2 trial of agenT-797 with the first patient dosed in Ukraine.
0 · Reply
OpenOutcrier
OpenOutcrier May. 28 at 1:16 PM
$INKT (+10.0% pre) MiNK Therapeutics doses first patient in phase 2 lung injury trial https://ooc.bz/l/103910
0 · Reply
IronManResurrection
IronManResurrection May. 23 at 6:40 PM
$IBRX can’t say it enough, if $INKT wins we WIN the hearts and minds of all the up and coming immunotherapies!
0 · Reply
enkemm
enkemm May. 22 at 2:13 PM
$INKT So...at the end of March, the short interest was about 140,000 shares, and at the end of April it was 97,000 shares. I believe that given the plethora of favorable news regarding INKT in May, that the short interest has dwindled to a small puddle of puke. You may detect that I absolutely despise shorts, and their manipulation of low volume tiny stocks like INKT. Every breath they take is antithetical to true investment, and they lurk in the shadows toward the bottom of the barrel of capitolism.
0 · Reply
Macroghost
Macroghost May. 22 at 11:40 AM
Pls find part 2 of 2 here. If you haven’t watched part 1 , it’s linked in the description. Happy Friday $IBRX $INKT This Tiny Stock Could 100x on $IBRX Partnership (Part 2 of 2) https://youtu.be/Rqy65EP0w6g
0 · Reply
Macroghost
Macroghost May. 21 at 5:03 PM
$IBRX $INKT Part 1 of 2 https://x.com/deepvalue69420/status/2057507318296977779?s=46&t=Rxc_O1GTw1wx9_JXMbIsSg
0 · Reply
Spartrap
Spartrap May. 21 at 2:02 PM
$INKT so I guess now the question everyone is left hanging with is, what does $IBRX intend to do now with that promising data? We now a couple months back they intended to setup two trials of anktiva in combo with agenT-797 in pneumonia (now withdrawn) and there were words about a "minority investment".. Did those discussions failed to lead to an agreement or were they just waiting for this publication to disclose it? I guess we'll know soon. I'm hopeful for a deal, that would be good for both companies, but either way, INKT is golden with its own P2 in ARDS already running with preliminary results before EOY
3 · Reply
Tigertkbc
Tigertkbc May. 20 at 9:59 PM
$INKT Great news! Little reaction price wise. I do think we have the science. Need more to understand that.
0 · Reply
focafoca99
focafoca99 May. 20 at 3:23 PM
$INKT presented new ATS 2026 data on agenT-797, showing pathogen suppression and lung immune restoration.
0 · Reply
Turnpiker
Turnpiker May. 20 at 12:21 AM
0 · Reply
Spartrap
Spartrap May. 19 at 6:37 PM
$INKT Hammond to present data tomorrow at the ATS. Combo with $IBRX's drug against a rare fungal infection. Intriguing stuff
0 · Reply
BenUnknown
BenUnknown May. 16 at 10:09 PM
0 · Reply
enkemm
enkemm May. 16 at 9:43 AM
$INKT Really....$3.00 stock at best. Why don't you just get up on your soap box and scream..."I'm a SHORT, I want to make money, so SELL all you imbeciles...SELL". Perhaps you believe investors in speculative stocks such as INKT to be cretins, but if this is at best a $3.00 stock then I bow to your tremendous intellect and must immediately liquidate my entire portfolio built over 50 years of incompetent investing. Really Brian....come on Man.
0 · Reply